glp 1 agonist metformin Clinical Focus on GLP-1 Agonists in Type 2 Diabetes Mellitus Disproportionality analysis of GLP-1 receptor

These agents include semaglutide (Ozempic for diabetes, Wegovy for obesity), liraglutide (Victoza for diabetes, Saxenda for obesity), dulaglutide (Trulicity, diabetes only), and tirzepatide (Mounjaro for diabetes, Zepbound for obesity)with tirzepatide being a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist

Side effects included nausea (16% of patients), diarrhea (2%) and vomiting (2%) [38]

Despite the rejection, CMS has indicated that it might cover obesity medication in future rulemaking

However, survodutide is further along in clinical development with Phase 3 trials fully enrolled and FDA Breakthrough Therapy Designation for MASH, where it has shown strong efficacy

Are there alternatives for patients who cant tolerate metformin

[DOI] [Google Scholar] 27.Jia G., Hill M